SCHEMBL2921667

SCHEMBL2921667

COC(=O)c1ccc2c(c1C)NC(=O)C2=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.53
LIG1 P18858 1/20 0.44
DAO P14920 1/20 0.44
CHEK1 O14757 1/20 0.42
MAPT P10636 2/20 0.42
MITF O75030 1/20 0.42
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
ROCK2 O75116 1/20 0.39
CSF1R P07333 1/20 0.39
KDR P35968 1/20 0.39
FLT3 P36888 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
CDK5 Q00535 1/20 0.39
ROCK1 Q13464 1/20 0.39
SLK Q9H2G2 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
CYP46A1 Q9Y6A2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27336587 0.82 LIG1 (0.60) CES1LIG1DAOCHEK1MAPT
SCHEMBL3365625 0.79 LIG1 (0.66) CES1LIG1DAOMAPTMITF
SCHEMBL28302945 0.75 CHEK1 (0.42) CES1CHEK1MAPTMITFKDM4E
SCHEMBL3083667 0.73 CES1 (0.59) CES1LIG1DAOMAPTKDM4E
SCHEMBL3422644 0.73 CA12 (0.54) MAPTKDM4EGLAGAAFFAR4
SCHEMBL18666975 0.73 TP53 (0.49) CHEK1MAPTMITFKDM4EGAA
SCHEMBL18666974 0.73 CHEK1 (0.44) CHEK1MAPTMITFROCK2CSF1R
SCHEMBL18666980 0.73 ALOX5 (0.51) CHEK1MAPTMITFKDM4EROCK2
SCHEMBL2892415 0.72 CES1 (0.67) CES1LIG1DAOCASP3L3MBTL1
SCHEMBL23018417 0.71 CHEK1 (0.42) CHEK1MAPTMITFKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024133619-A1 NEW PROCESS FOR THE MANUFACTURE OF MDM2-P53 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-06-27 WO disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K CES1 1594/4885LIG1 1516/4885DAO 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.